Launched or under launch (2013-2014): Australia & New Zealand, Canada, Djibouti, Dubai, Egypt, Ivory Coast, Jordan, Lebanon, Libya, Malaysia, Mauritania, Middle East, Moldavia & Montenegro, Romania, Serbia, South Africa, Tunisia.
50mL Class IIa Medical Device for the treatment of Lesions
of Psoriasis, Eczema & Dermatitis (Official Indication)
PSORIASIS, ECZEMA, DERMATITIS (PED)
Physiopathology: Although Psoriasis, Eczema & Dermatitis are classified as different diseases, all histological sections of PE&D lesions show a common picture: excessive & uncontrolled growth of dermal cells, very high numbers of cytokine-secreting immunological cells, inflammation & secondary microbial contamination. Vitrobio identified >8 cytokines acting as cell growth factors, inducing inflammation, & maintaining the excessive cell growth caused by the cytokine cascade.
Ideal Treatment Approach: As autoimmune dysfunctions cannot presently be treated, normalizing cell growth by identifying & inhibiting growth factor-like cytokines is the only symptomatic treatment to ease symptoms of the disease.
Currently Available Treatments:
- Topical cell growth regulators: none
- All the currently available treatments such as: anti-inflammatory drugs, corticosteroids, Vitamin A & D analogues, immune-modulators, immune-suppressants, as well as specific inhibitors of T-cells or leukocytes, interleukin inhibitors, TNF-alpha blockers, and anti-mitotic drugs, are directed to block only one or two cytokines or cellular functions, whereas their systemic presence induces serious side effects.
VITROBIO‘s Completely NEW Therapeutic Approach: Protein Hypothesis for Innovative Dermatological Treatments.
Vitrobio identified the topical cell growth-stimulating cytokines (>8), and cytokines being proteins, we used specific plant procyanidins to neutralize only those cytokines involved in PED. These Procyanidins are mixed with a very highly osmotic solution used as excipient for topical application (Patents: PCT/FR99/10340 & PCT/EP2013/061835) so as to generate an outward flow of hypotonic liquid from the lesion as a mechanical means to remove conjugated cytokines & other contaminants. This new approach of treating skin diseases involving abnormal cell growth is also patented (PCT/EP2010/067861).
Product Presentation: 50mL Tube containing a viscous, brownish solution for topical application.
Posology: Dose depends on lesion size; 2-3 applications per day in the beginning, then once a day until complete recovery.
Regulatory Status: Due to the mechanical & topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class IIa Medical Device in Europe.
Contraindications: Cannot be applied on smooth, non-porous skin; requires light scraping if the skin is keratinized.
Side Effects: None
Clinical Efficacy: Full study published in Int J Modern Pharmaceutical Research, Vol 2, Issue 4, July 2013. ISSN 2319-5878.
Conclusion: 1st topical mechanical growth factor inhibitor to treat open lesions of PSORIASIS, ECZEMA, DERMATITIS
Conclusion: 1st topical CYTOKINE Inhibitor to treat open lesions of
PSORIASIS, ECZEMA, DERMATITIS